Invesaro

Stocks Comparison

Anheuser-Busch InBev vs CVS HEALTH: revenue, profit, margins and growth compared

Anheuser-Busch InBev brought in $59.3B of revenue in fiscal 2025, CVS HEALTH $402.1B in fiscal 2025. Revenue changed by -0.7% at Anheuser-Busch InBev and +7.8% at CVS HEALTH on the year before, so CVS HEALTH grew faster. Anheuser-Busch InBev kept 11.5% of its revenue as net profit, CVS HEALTH 0.4%. Free cash flow was $11.2B at Anheuser-Busch InBev and $7.8B at CVS HEALTH.

Side by side, latest fiscal year

BUDCVS
Fiscal year endedFY2025 (December 31, 2025)FY2025 (December 31, 2025)
Revenue$59.3B$402.1B
Revenue growth-0.7%+7.8%
Net income$6.8B$1.8B
Net margin11.5%0.4%
Free cash flow$11.2B$7.8B
Free cash flow margin18.9%1.9%
Earnings per share (diluted)$3.39$1.39
Cash$11.6B$8.5B
Debt$73B$64.6B
Price to earningsn/a64.1
Market value$153.8B$114B
Dividend yieldn/a2.98%
Rank by revenue in sector#8 of 125 · Consumer staples#1 of 125 · Consumer staples

Over the years

Revenue
BUD FY2018: $53BBUD FY2019: $52.3BBUD FY2020: $46.9BBUD FY2021: $54.3BBUD FY2022: $57.8BBUD FY2023: $59.4BBUD FY2024: $59.8BBUD FY2025: $59.3BCVS FY2018: $194.6BCVS FY2019: $256.8BCVS FY2020: $268.7BCVS FY2021: $292.1BCVS FY2022: $322.5BCVS FY2023: $357.8BCVS FY2024: $372.8BCVS FY2025: $402.1BFY18FY19FY20FY21FY22FY23FY24FY25
BUD $59.3BCVS $402.1B
Net income
BUD FY2018: $4.4BBUD FY2019: $9.2BBUD FY2020: $1.4BBUD FY2021: $4.7BBUD FY2022: $6BBUD FY2023: $5.3BBUD FY2024: $5.9BBUD FY2025: $6.8BCVS FY2018: -$594MCVS FY2019: $6.6BCVS FY2020: $7.2BCVS FY2021: $8BCVS FY2022: $4.3BCVS FY2023: $8.3BCVS FY2024: $4.6BCVS FY2025: $1.8BFY18FY19FY20FY21FY22FY23FY24FY25
BUD $6.8BCVS $1.8B
Net margin
BUD FY2018: 8.2%BUD FY2019: 17.5%BUD FY2020: 3.0%BUD FY2021: 8.6%BUD FY2022: 10.3%BUD FY2023: 9.0%BUD FY2024: 9.8%BUD FY2025: 11.5%CVS FY2018: -0.3%CVS FY2019: 2.6%CVS FY2020: 2.7%CVS FY2021: 2.7%CVS FY2022: 1.3%CVS FY2023: 2.3%CVS FY2024: 1.2%CVS FY2025: 0.4%FY18FY19FY20FY21FY22FY23FY24FY25
BUD 11.5%CVS 0.4%
Revenue growth
BUD FY2019: -1.3%BUD FY2020: -10.4%BUD FY2021: +15.8%BUD FY2022: +6.4%BUD FY2023: +2.8%BUD FY2024: +0.7%BUD FY2025: -0.7%CVS FY2019: +32.0%CVS FY2020: +4.6%CVS FY2021: +8.7%CVS FY2022: +10.4%CVS FY2023: +10.9%CVS FY2024: +4.2%CVS FY2025: +7.8%FY19FY20FY21FY22FY23FY24FY25
BUD -0.7%CVS +7.8%
Free cash flow
BUD FY2018: $10.1BBUD FY2019: $8.9BBUD FY2020: $7.1BBUD FY2021: $9.2BBUD FY2022: $8.1BBUD FY2023: $8.6BBUD FY2024: $11.2BBUD FY2025: $11.2BCVS FY2018: $6.8BCVS FY2019: $10.4BCVS FY2020: $13.4BCVS FY2021: $15.7BCVS FY2022: $13.5BCVS FY2023: $10.4BCVS FY2024: $6.3BCVS FY2025: $7.8BFY18FY19FY20FY21FY22FY23FY24FY25
BUD $11.2BCVS $7.8B

Fiscal years as each company reports them; the two may end in different months.

Questions about Anheuser-Busch InBev and CVS HEALTH

Which is bigger by revenue, Anheuser-Busch InBev or CVS HEALTH?

CVS HEALTH is bigger by revenue: $402.1B in fiscal 2025, against $59.3B for Anheuser-Busch InBev in fiscal 2025.

Which keeps more of its revenue as profit, Anheuser-Busch InBev or CVS HEALTH?

Anheuser-Busch InBev had a net margin of 11.5% in fiscal 2025; CVS HEALTH had 0.4% in fiscal 2025.

Which grew revenue faster, Anheuser-Busch InBev or CVS HEALTH?

In their latest fiscal years revenue changed by -0.7% at Anheuser-Busch InBev and +7.8% at CVS HEALTH.

Where do these numbers come from?

From the annual reports each company files with the SEC (10-K, or 20-F and 40-F for foreign companies), read from their XBRL data. Margins and growth are simple arithmetic on those figures. Nothing here is a recommendation.

More comparisons

Compare more companies